1,3-dibutyl-7-(3-nitro-benzenesulfonyl)-3,7-dihydro-purine-2,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,3-dibutyl-7-(3-nitro-benzenesulfonyl)-3,7-dihydro-purine-2,6-dione
• 英文别名: 1,3-dibutyl-7-(3-nitrophenyl)sulfonylpurine-2,6-dione
• 化学式: C₁₉H₂₃N₅O₆S
• 分子量: 449.488
• InChiKey: PLKQOVPUGHYTLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  147
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1,3-二-正-丁基黄嘌呤 、 3-硝基苯磺酰氯 在 i-Pr₂NEt 作用下， 以 二氯甲烷 为溶剂， 以79%的产率得到1,3-dibutyl-7-(3-nitro-benzenesulfonyl)-3,7-dihydro-purine-2,6-dione
  参考文献：
  名称：

  Method of treating bone loss by stimulation of calcitonin

  摘要：

  化合物的化学式为R1和R2，分别是烷基（1至6个碳原子）、烯丙基或取代的烯丙基（3至6个碳原子）；R3是氢、烷基（1至6个碳原子）或环烷基（3至10个碳原子）；R4是苯基或萘基，取代有烷基（1至6个碳原子）、烷氧基（1至6个碳原子）或NR5R6；取代或未取代的苯基烷基，其中烷基含1至6个碳原子；取代或未取代的5至10元杂环芳基，含1至3个杂原子，选自N、S和O；取代或未取代的环烷基（3至10个碳原子）；或取代或未取代的环烷基烷基（4至10个碳原子）；若R1和R2为烷基，则苯基或萘基取代为NR5R6。这些化合物可用于治疗与骨质流失相关的各种疾病，通过增加转录和提高血浆降钙素水平。这些疾病包括但不限于：帕吉特病、绝经后骨质疏松症、老年性骨质疏松症和糖皮质激素诱导性骨质疏松症。

  公开号：

  US06221874B1

文献信息

• Method of treating bone loss by stimulation of calcitonin
  申请人：American Home Products Corporation

  公开号：US06221874B1

  公开（公告）日：2001-04-24

  Compounds of the formula R1 and R2 are independently alkyl of 1 to 6 carbon atoms, allyl, or substituted allyl of 3 to 6 carbon atoms; R3 is hydrogen, alkyl of 1 to 6 carbon atoms, or cycloalkyl of 3 to 10 carbon atoms; and R4 is phenyl or naphthyl substituted with alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms or NR5R6; substituted or unsubstituted phenylalkyl wherein the alkyl group contains 1 to 6 carbon atoms; substituted or unsubstituted 5 to 10 membered heteroaryl having 1 to 3 heteroatoms selected from N, S and O; substituted or unsubstituted cycloalkyl of 3 to 10 carbon atoms; or substituted or unsubstituted cycloalkylalkyl of 4 to 10 carbon atoms; provided that phenyl or naphthyl is substituted with NR5R6 when R1 and R2 is alkyl, are useful in the treatment of various disorders associated bone loss by increased transcription and elevation of plasma calcitonin levels. Such disorders include, but are not limited to: Paget's Disease, post menopausal osteoporosis, senile osteoporosis, and glucocorticoid-induced osteoporosis.

  化合物的化学式为R1和R2，分别是烷基（1至6个碳原子）、烯丙基或取代的烯丙基（3至6个碳原子）；R3是氢、烷基（1至6个碳原子）或环烷基（3至10个碳原子）；R4是苯基或萘基，取代有烷基（1至6个碳原子）、烷氧基（1至6个碳原子）或NR5R6；取代或未取代的苯基烷基，其中烷基含1至6个碳原子；取代或未取代的5至10元杂环芳基，含1至3个杂原子，选自N、S和O；取代或未取代的环烷基（3至10个碳原子）；或取代或未取代的环烷基烷基（4至10个碳原子）；若R1和R2为烷基，则苯基或萘基取代为NR5R6。这些化合物可用于治疗与骨质流失相关的各种疾病，通过增加转录和提高血浆降钙素水平。这些疾病包括但不限于：帕吉特病、绝经后骨质疏松症、老年性骨质疏松症和糖皮质激素诱导性骨质疏松症。
• US6221874B1
  申请人：——

  公开号：US6221874B1

  公开（公告）日：2001-04-24
• Novel and Selective Calcitonin-Inducing Agents
  作者：Adam M. Gilbert、Stephen Caltabiano、Denise Roberts、Sam F. W. Sum、Gerardo D. Francisco、Kitae Lim、Magda Asselin、John W. Ellingboe、Yogendra Kharode、Anna Cannistraci、Rita Francis、Mark TrailSmith、David Gralnick

  DOI：10.1021/jm990558l

  日期：2000.3.1

  A series of xanthine sulfonamides is presented as a class of calcitonin (CT) inducers - a potentially new method for treating diseases associated with postmenopausal bone loss such as osteoporosis. We have found that certain di-n-butylxanthine sulfonamides 4 upregulate CT transcription in a CT-luciferase reporter gene assay (CT-luci) and increase the production and release of CT in a CT secretion/RIA assay (CTS). In addition, these compounds do not have potent PDE4 inhibitory activity as do the related xanthine methylene ketones such as denbufyllene (2). One compound in particular (9) shows a transcription activation ratio (TAR) of 2.1 in CT-luci, a CTS increase of 3.6-fold, and a PDE4 (phosphodiesterase type IV) IC50 = 4.1 mu M. In addition, this compound showed a statistically significant 47% trabecular bone protection in ovariectomized-induced osteopenia (OVX) rats as determined by assay when administered for 4 weeks at 30 mg/kg/day, i.p. by quantitative computed tomography (QCT). When administered p.o., compound 9 shows 50% trabecular bone protection when administered for 3 weeks at 50 mg/kg/day, i.p. This compared with salmon CT which shows 62% trabecular bone protection when administered at 50 IU/kg/day for 4 weeks.